MetaCap

Inventiva S.A. American Depository Shares (IVA) vs Oric Pharmaceuticals (ORIC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inventiva S.A. American Depository Shares (IVA) has outperformed Oric Pharmaceuticals (ORIC) over the past year, losing 27.0% versus a loss of 36.7%. Over five years, ORIC leads with a -48.6% price change compared with -76.5% for IVA. Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $750.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IVA-26.98%ORIC-36.66%
+71%+15%-42%
Nov 21, 20251 yearNov 20, 2026
IVA-76.21%ORIC-55.39%
+11%-40%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IVA versus ORIC key metrics
MetricIVAORIC
Share price$3.14$7.36
Market cap$750.78M$764.94M
1-day change-8.99%-4.42%
YTD return-32.47%-10.02%
1-year return-26.98%-36.66%
5-year return-76.53%-48.64%
EPS (TTM)$-0.62$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-49.63M$-129.47M
52-week high$7.29$14.68
52-week low$2.82$7.23
Distance from 52-week high-56.93%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+359.24%+194.97%
Average volume2.40M1.59M
Shares outstanding239.10M103.93M
Employees87111
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Inventiva S.A. American Depository Shares

IVA stock →

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

IVA vs ORIC FAQ

Which is bigger, Inventiva S.A. American Depository Shares or Oric Pharmaceuticals?

Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $750.78M for Inventiva S.A. American Depository Shares (IVA).

Which stock has performed better over the past year, IVA or ORIC?

IVA returned -26.98% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.

Are Inventiva S.A. American Depository Shares and Oric Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons